Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Future opportunities with biological drugs in health care

Virtuella Wed 24 Mar 2021 at 09:00-10:45

Biological drugs are an area in rapid development where Sweden has a leading position. In the continued development, collaboration and innovative capacityare needed, among other things. Welcome to explore the future possibilities in biological drugs together with important actors during two webcast seminars in March 2021. The second seminar is about future possibilities with biological drugs in health care.

This web page has been machine translated. If there are any uncertainties, please refer to the Swedish text.

Future opportunities with biological drugs in health care

There are great opportunities with the use of biological drugs in Swedish healthcare. To succeed, a stronger connection is needed between research, business and healthcare, a developed international collaboration and a focus on developing new individualized diagnostics and treatment.

You will meet, among others, representatives from healthcare, companies, researchers and financiers. They give their views on the area and how it can be developed in Sweden. There will be room to ask questions and contribute thoughts in the discussion.

Read more about the first seminar March 17 on Sweden's success factors in the development of biological drugs


Moderator Karin Aase, Vinnova

Introduction to healthcare opportunities and challenges with biological drugs today and in the future.

  • Prerequisites and opportunities for ATMP, Johan Hyllner, AstraZeneca

Actors from the pharmaceutical industry, research, authorities and innovation environments present their perspectives.

  • Professor Stephan Mielke, Head of Cell Therapy and Allogeneic Stem Cell Transplantation, Karolinska University Hospital
  • CAR-T from EMA approval to clinical practice - the Novartis experience, Rudi Subirà, Novartis
  • Opportunities and challenges with virtual clinical trials, Gunilla Andrew-Nielsen, The Medical Products Agency
  • System challenges around advanced therapies, Kristina Kannisto, Karolinska Centrum for Cell Therapy

Question time

Priorities and funding opportunities within Horizon Europe and internationally

  • Nadine Schweizer, Vinnova

During breaks and after the seminar is the opportunity to explore digital print by ongoing project within the program Biologics.

The seminars are arranged within the framework of Vinnova's programme Biological Medicines.

The program has over the years 2016-2019 made four calls that led to the funding of 30 project including three centers, with 270 million.

Read more about the projects within Vinnova's programme Biological drugs

Sometimes we photograph or video record our activities. If you don't want to participate in photos or videos, please let us when you arrive.


Mats Jarekrans

Programme Director for Berzelii Centra

+46 8 473 31 85

Others also read

Last updated 27 January 2021

Page statistics